Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Cash from Financing Activities: 2015-2025

Historic Cash from Financing Activities for Wave Life Sciences (WVE) over the last 11 years, with Sep 2025 value amounting to $32.7 million.

  • Wave Life Sciences' Cash from Financing Activities fell 83.95% to $32.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.5 million, marking a year-over-year decrease of 73.30%. This contributed to the annual value of $253.9 million for FY2024, which is 91.57% up from last year.
  • As of Q3 2025, Wave Life Sciences' Cash from Financing Activities stood at $32.7 million, which was up 179.59% from $11.7 million recorded in Q2 2025.
  • In the past 5 years, Wave Life Sciences' Cash from Financing Activities registered a high of $203.7 million during Q3 2024, and its lowest value of $17,000 during Q3 2022.
  • Over the past 3 years, Wave Life Sciences' median Cash from Financing Activities value was $14.5 million (recorded in 2024), while the average stood at $39.5 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first surged by 177,757.89% in 2021, then plummeted by 99.84% in 2022.
  • Quarterly analysis of 5 years shows Wave Life Sciences' Cash from Financing Activities stood at $33.8 million in 2021, then crashed by 99.84% to $55,000 in 2022, then soared by 170,740.00% to $94.0 million in 2023, then crashed by 62.77% to $35.0 million in 2024, then tumbled by 83.95% to $32.7 million in 2025.
  • Its last three reported values are $32.7 million in Q3 2025, $11.7 million for Q2 2025, and $4.2 million during Q1 2025.